


Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-Apr-2021
 Document Type: USP Monographs
 DocId: GUID-680402AF-D503-47EC-B416-3AE520E5F775_5_en-US
 DOI: https://doi.org/10.31003/USPNF_M3250_05_01
 DOI Ref: 84c7l

© 2025 USPC
 Do not distribute

Riluzole



$C_8H_5F_3N_2OS$ 234.20

2-Benzothiazolamine, 6-(trifluoromethoxy)-;

2-Amino-6-(trifluoromethoxy)benzothiazole CAS RN®: 1744-22-5; UNII: 7LJ087RS6F.

DEFINITION

Riluzole contains NLT 98.0% and NMT 102.0% of the labeled amount of $C_8H_5F_3N_2OS$, calculated on the anhydrous basis.

IDENTIFICATION

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Mobile phase: Acetonitrile and water (9:11)

Standard solution: 0.05 mg/mL of [USP Riluzole RS](#) in *Mobile phase*

Sample solution: 0.05 mg/mL of Riluzole in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 221 nm

Column: 4.6-mm × 15-cm; 5-μm packing L1

Flow rate: 2.0 mL/min

Injection size: 20 μL. [NOTE—Monitor for 3 times the retention time of riluzole.]

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of $C_8H_5F_3N_2OS$ in the portion of Riluzole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Riluzole RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Riluzole in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the anhydrous basis

IMPURITIES**INORGANIC IMPURITIES**

- **RESIDUE ON IGNITION (281):** NMT 0.1%, a 1.5-g of sample used

ORGANIC IMPURITIES• **PROCEDURE**

Mobile phase: Proceed as directed in the Assay.

System suitability solution: 500 µg/mL of [USP Riluzole RS](#) and 0.5 µg/mL [USP Riluzole Related Compound A RS](#) in *Mobile phase*

Standard solution: 0.5 µg/mL of [USP Riluzole RS](#) in *Mobile phase*

Sample solution: 500 µg/mL of Riluzole in *Mobile phase*

Chromatographic system: Proceed as directed in the Assay, and use an injection volume of 100 µL. [NOTE—Monitor for 11 times the retention time of riluzole.]

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Resolution: NLT 1.5 between Riluzole and riluzole related compound A, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Identify the impurities using the relative retention times shown in [Impurity Table 1](#). Calculate the percentage of each impurity in the portion of Riluzole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of the impurity from the *Sample solution*

r_S = peak response of Riluzole from the *Standard solution*

C_S = concentration of [USP Riluzole RS](#) in the *Standard solution* (µg/mL)

C_U = concentration of Riluzole in the *Sample solution* (µg/mL)

F = relative response factor relative to riluzole

Acceptance criteria

Individual impurities: See [Impurity Table 1](#).

Total impurities: NMT 1.0%

Impurity Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Riluzole	1.0	—	—
Riluzole related compound A ^a	1.3	0.16	0.1
Bromoriluzole ^b	1.9	0.54	0.2
Dibromotrifluoro methoxyaniline ^c	7.4	0.28	0.1
Any unspecified impurity	—	1.0	0.1

^a 4-(Trifluoromethoxy)aniline.

^b 4-Bromo-6-(trifluoromethoxy)benzothiazol-2-amine.

^c 2,6-Dibromo-4-(trifluoromethoxy)aniline.